Edition:
United Kingdom

Applied DNA Sciences Inc (APDN.OQ)

APDN.OQ on NASDAQ Stock Exchange Capital Market

0.56USD
23 Apr 2019
Change (% chg)

-- (--)
Prev Close
$0.56
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
146,660
52-wk High
$1.82
52-wk Low
$0.30

Latest Key Developments (Source: Significant Developments)

Applied DNA Sciences Says Entered Into Agreement With Unit Of Theracann
Wednesday, 3 Apr 2019 

April 3 (Reuters) - Applied DNA Sciences Inc ::APPLIED DNA SCIENCES SAYS ON MARCH 28, CO, UNIT ENTERED INTO PATENT & KNOW-HOW LICENSE & COOPERATION AGREEMENT WITH A UNIT OF THERACANN - SEC FILING.APPLIED DNA SCIENCES - UNDER AGREEMENT, A $5 MILLION NON-REFUNDABLE UP-FRONT LICENSING FEE IS PAYABLE TO CO AND ITS UNIT OVER A FOUR-MONTH PERIOD.  Full Article

Applied DNA Reports Q1 Loss Per Share Of $0.11
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Applied DNA Sciences Inc ::APPLIED DNA REPORTS FISCAL FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.11.Q1 REVENUE ROSE 37 PERCENT TO $884,000.  Full Article

Applied Dna Announces Pricing Of $2.75 Million Offering Of Common Stock And Warrants
Friday, 21 Dec 2018 

Applied DNA Sciences Inc ::APPLIED DNA ANNOUNCES PRICING OF $2.75 MILLION OFFERING OF COMMON STOCK AND WARRANTS.APPLIED DNA SCIENCES INC - PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 5.5 MILLION SHARES OF ITS COMMON STOCK AND WARRANTS.APPLIED DNA SCIENCES INC - PRICING OF 5.5 MILLION COMMON SHARES AND WARRANTS TO BUY UP TO 5.5 MILLION SHARES OF COMPANY'S COMMON STOCK.APPLIED DNA SCIENCES INC - COMBINED OFFERING PRICE OF $0.50 PER SHARE.  Full Article

Applied DNA Sciences Q4 Loss Per Share $0.12
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Applied DNA Sciences Inc ::APPLIED DNA ANNOUNCES SELECTED PRELIMINARY UNAUDITED FISCAL 2018 YEAR END AND FOURTH QUARTER FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.12.Q4 REVENUE $1.2 MILLION.  Full Article

Applied DNA Sciences Shipped Over 8,000 Milligrams Of PCR-Produced Linear DNA In 12 Months
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Applied DNA Sciences Inc ::APPLIED DNA SCIENCES REACHES NEW MILESTONES IN THERAPEUTIC CONTRACT RESEARCH AND CONTRACT MANUFACTURING OF LINEAR DNA.APPLIED DNA SCIENCES - IN PAST 12 MONTHS, SHIPPED OVER 8,000 MILLIGRAMS OF PCR-PRODUCED LINEAR DNA.  Full Article

Wuhan Thalys Medical Technology and partner jointly sign contract with Pingdu People's Hospital
Monday, 8 Jan 2018 

Jan 8(Reuters) - Wuhan Thalys Medical Technology Inc <603716.SS>:Says it and China Resources Shandong Pharmaceutical Co Ltd jointly signed contract with Pingdu People's Hospital, regarding centralized purchasing and supply of test reagent and consumable.  Full Article

Wuhan Thalys Medical Technology signs contracts with Wuhan Hospital of Traditional Chinese Medicine
Monday, 8 Jan 2018 

Jan 8(Reuters) - Wuhan Thalys Medical Technology Inc <603716.SS>:Says it signed contracts with Wuhan Hospital of Traditional Chinese Medicine, regarding centralized delivery of test reagent and consumable.  Full Article

Applied DNA Sciences Q4 Revenue $1.1 Million
Thursday, 28 Dec 2017 

Dec 28 (Reuters) - Applied Dna Sciences Inc ::APPLIED DNA SCIENCES REPORTS YEAR END AND FISCAL FOURTH QUARTER RESULTS.Q4 LOSS PER SHARE $0.10.Q4 REVENUE FELL 30 PERCENT TO $1.1 MILLION.  Full Article

Wuhan Thalys Medical Technology unit sets up medical tech unit in Tai'an City
Tuesday, 19 Dec 2017 

Dec 19(Reuters) - Wuhan Thalys Medical Technology Inc <603716.SS>:Says co's Jinan-based medical technology unit sets up a wholly owned medical technology unit in Tai'an City, with registered capital of 10 million yuan .  Full Article

Applied DNA And Colorcon To Collaborate To Commercialize Product Authentication Technology
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Applied Dna Sciences Inc ::APPLIED DNA AND COLORCON ANNOUNCE COLLABORATION TO COMMERCIALIZE PRODUCT AUTHENTICATION TECHNOLOGY FOR PHARMACEUTICAL AND NUTRACEUTICAL INDUSTRY.APPLIED DNA SCIENCES INC - CO, COLORCON INC HAVE ENTERED INTO A TECHNOLOGY LICENSE MEMORANDUM OF UNDERSTANDING.APPLIED DNA SCIENCES - DEAL TO COMMERCIALIZE PLATFORM FOR TRACEABILITY DIRECTLY ON DOSE, IS INTENDED TO REDUCE RISKS ASSOCIATED WITH COUNTERFEIT MEDICATIONS.  Full Article